Blog

  • Qloud Games raises $5m in seed funding round

    Qloud Games raises $5m in seed funding round

    Sydney-based studio Qloud Games has raised $5 million in a seed funding round led by Bitkraft Ventures and GFR Fund.

    The independent developer plans to use the investment to support development of its MMO Loftia. A16Z’s Andreessen Horowitz also participated in the funding, as well as 1Up Fund and Gaingels.

    Qloud Games co-founders Michael Su and Martina Qin invested $500,000 into the studio, and raised $1.3 million on Kickstarter in 2024 with over 16,700 backers.

    “With Loftia, we’re creating the kind of world we wish existed – one where people work together to create a brighter future,” said CEO Michael Su.

    “Thanks to the support of Bitkraft, GFR Funding, A16Z, and our Kickstarter backers, we’re excited to bring Loftia to life.”

    Bitkraft Ventures partner Jasper Brand added: “Michael and Martina have put everything into Loftia – investing over $500,000 of their own capital earned from a Canva ESOP, rallying a record-breaking Kickstarter, and building a 600,000 strong community before launch.

    “With a successful Alpha already behind them, funding secured through launch, and a real distribution edge in the massive but undeserved cozy genre, they’re poised to bring live service, cross platform, and social play to a new generation of players – and build a world-class studio from Australia with global impact.”

    Qloud Games was co-founded by Michael Su, Martina Qin, and Eric Mallon in 2022. Its team currently consists of 30 developers from indie and AAA game studios from across the globe.

    Continue Reading

  • Microsoft Entra ID attack weakens authentication

    Microsoft Entra ID attack weakens authentication

    Sessions within Entra ID can be hijacked if the correct authentication is disabled. A new attack allows malicious actors to perform a FIDO downgrade and take over accounts.

    Fortunately for Microsoft, it was not cyber attackers but Proofpoint researchers who discovered the exploit. The technical ingenuity lies in the simplicity of the execution. The attackers simply modify the browser identification, causing Microsoft Entra ID to automatically disable FIDO authentication and generate an error message. This error prompts the user to choose an alternative verification method.

    The attack starts when the target follows a phishing link via email or SMS. The malicious website uses a customized phishlet within the Evilginx adversary-in-the-middle (AiTM) framework. A phishlet is essentially a configuration file for phishing pages. This site uses a proxy for the legitimate Microsoft Entra ID forms, but at the same time spoofs an unsupported browser user agent.

    Bypassing phishing-resistant authentication

    For a successful attack, the researchers needed a browser without FIDO support. By emulating Safari on Windows, a combination of browser and OS that does not support FIDO authentication, users are forced to switch to alternative verification methods such as the Microsoft Authenticator app or SMS codes.

    Once the user switches to a weaker authentication method, the AiTM proxy can intercept both the account details and the MFA token or session cookie. The attacker then imports the stolen cookie into their own browser, gaining full access to the victim’s account.

    Limited practical application

    So far, this technique has not been observed in real attacks. Proofpoint indicates that cybercriminals are currently focusing on easier targets, such as accounts without MFA protection. However, the risk remains, especially for targeted attacks on specific organizations or individuals. A large-scale campaign could quickly take over one or a few accounts, resulting in potential data leaks or IP theft.

    Some readers may be familiar with this technique. However, the attack differs from an earlier FIDO downgrade technique called “PoisonSeed” developed by Expel researchers. That method ultimately proved impractical due to proximity requirements that caused fraudulent authentication requests to fail. In other words, it was a false alarm.

    Security measures

    Organizations can mitigate the risk by disabling fallback authentication methods where possible. Activating additional checks and confirmations when such processes are triggered can also help.

    End users should be wary of sudden requests to use a different authentication method than the registered passkey. This is often a red flag indicating that something is wrong with the login process.

    Although the attack does not demonstrate a vulnerability in FIDO itself, it proves that the system can be circumvented. This is a crucial weakness, especially given the increased adoption of FIDO-based authentication in critical environments, where the technology is presented as extremely phishing-resistant. Ultimately, all users must use FIDO-supported browsers, which is difficult to guarantee.

    Continue Reading

  • This is the only OLED TV to tempt me this year – but I still wouldn’t recommend upgrading yet

    This is the only OLED TV to tempt me this year – but I still wouldn’t recommend upgrading yet

    With What Hi-Fi?’s 48-inch Panasonic Z90B review now live, my group test of this year’s small-ish OLED TVs has come to an end – for now.

    And to be clear, it is an utterly fantastic set. So much so that, as well earning a five-star rating from the team, it’s also the one I would 100 per cent pick if I was on the market for a new set this year.

    Continue Reading

  • Asian shares are mixed after days of gains driven by hopes for US rate cuts

    Asian shares are mixed after days of gains driven by hopes for US rate cuts

    MANILA, Philippines — Asian shares were mixed on Thursday after days of gains driven by hopes for lower U.S. interest rates, while U.S. futures slipped.

    Bitcoin rose more than 3% to a new record of over $123,000, according to CoinDesk.

    In Tokyo, the Nikkei 225 fell 1.4% to 42,657.94 as investors sold to lock in recent gains that have taken the benchmark to all-time records.

    The Japanese yen rose against the dollar after U.S. Treasury Secretary Scott Bessent said in an interview with Bloomberg that Japan was “behind the curve” in monetary tightening. He was referring to the slow pace of increases in Japan’s near-zero interest rates.

    Low interest rates tend to make the yen weaker against the dollar, giving Japanese exporters a cost advantage in overseas sales.

    The dollar fell to 146.55 Japanese yen early Thursday, down from 147.39 yen. The euro fell to $1.1703 from $1.1705.

    In Chinese markets, Hong Kong’s Hang Seng index shed less than 0.1% to 25,597.85, while the Shanghai composite index gained 0.2% to 3,690.88.

    South Korea’s Kospi slid 0.3% to 3,215.61, while Australia’s S&P ASX 200 index added 0.5% to 8,871.80.

    Taiwan’s TAIEX fell 0.4%, while India’s Sensex edged 0.1% higher.

    “Asian markets opened today like a party that ran out of champagne before midnight — the music still playing, but the dance floor thinning out,” Stephen Innes of SPI Asset Management said in a commentary.

    The futures for the S&P 500 and the Dow Jones Industrial Average were down less than 0.1%.

    On Wednesday, U.S. stocks ticked higher, extending a global rally fueled by hopes the Federal Reserve will cut U.S. interest rates.

    The S&P 500 rose 0.3% to 6,466.58, coming off its latest all-time high. The Dow climbed 1% to 44,922.27, while the Nasdaq composite added 0.1% to its own record set the day before, closing at 21,713.14.

    Treasury yields eased in the bond market in anticipation that the Fed will cut its main interest rate for the first time this year at its next meeting in September. Lower rates can boost investment prices and the economy by making it cheaper for U.S. households and businesses to borrow to buy houses, cars or equipment, though they risk worsening inflation.

    Stocks of companies on Wall Street that could benefit most from lower interest rates helped lead the way. PulteGroup climbed 5.4%, and Lennar rose 5.2% as part of a broad rally for homebuilders and others in the housing industry. Lower rates could make mortgages cheaper to get, which could spur more buying.

    The cryptocurrency exchange company Bullish ended its debut day of trading after an initial public offering of more than $10 billion with a gain of nearly 84% to $68 a share.

    The hopes for lower interest rates are helping to drown out criticism that the U.S. stock market has broadly grown too expensive after its big leap since hitting a low in April.

    President Donald Trump has angrily been calling for cuts to help the economy, often insulting the Fed Chair Jerome Powell while doing so.

    But the Fed has hesitated of the possibility that Trump’s sweeping higher tariffs could make inflation much worse. Fed officials have said they want to see more fresh data about inflation before moving.

    On Thursday, a report will show how bad inflation was at the wholesale level across the United States. Economists expect it to show inflation accelerated a touch to 2.4% in July from 2.3% in June.

    In other dealings early Thursday, U.S. benchmark crude rose 24 cents to $62.89 per barrel. Brent crude, the international standard, added 27 cents to $65.90 per barrel.

    Continue Reading

  • Škoda Vision O: Estate concept features aerodynamic exterior design taking Modern Solid to the next level

    Škoda Vision O: Estate concept features aerodynamic exterior design taking Modern Solid to the next level

    › The teaser video reveals initial exterior details of the upcoming concept estate car, showcasing an evolution of the Modern Solid design language

    › Exterior of the Vision O is defined by a clear focus on aerodynamics and distinctively drawn lines

    › The concept features narrow ‘T’ shaped taillights and a sloping roof, which includes elements of the contemporary feature for future Škoda estate models

    Mladá Boleslav, 14 August 2025 – Škoda Auto reveals the first exterior video of the Vision O design study, unveiling details of development of the Modern Solid design language. A glance at the sleekly styled rear of the estate model underlines the clear focus on aerodynamics. With the Vision O concept, Škoda Auto reinforces its leadership in the European estate segment and boldly sets a new course of innovation for future models.

    “With Vision O, we are consistently advancing our ‘Modern Solid’ design language, boosting its emotional appeal and further refining our brand identity. New design concept also highlights our commitment to pushing boundaries and continuously bringing innovation to future automotive design. Clear lines emphasize simplicity, showcasing totally that we remain true to our brand values. Vision O is extremely practical for everyday use and brings surprising and thoughtful details.”

    Oliver Stefani, Head of Design

    Smooth lines and distinctive light motif
    The video teaser showcases a new B-pillar design, which seamlessly connects to the rear of the body. The sloping roof with a split roof spoiler leads to the narrow taillights, which forms a characteristic ‘T’ shape, evoking the typical ‘four-eyed’ lighting motif. The Škoda lettering and the model designation ‘Vision O’ on the fifth door complements the design of the rear bumper, emphasising the concept’s unique, modern exterior styling.

    Introduction of the new concept in September
    The world premiere of the Škoda Vision O concept, which will preview the future of Škoda in the estate model segment, will take place on the 8th of September 2025 in Munich. The presentation will also be available to all viewers online via Škoda Auto’s YouTube channels.

    Continue Reading

  • Initial treatment strategies on survival outcomes of early-stage saliv

    Initial treatment strategies on survival outcomes of early-stage saliv

    Introduction

    Mucosa-associated lymphoid tissue (MALT) lymphomas, an indolent subtype of extranodal B-cell non-Hodgkin lymphoma, represent approximately 8% of all lymphoma cases.1,2 This malignancy typically emerges in response to chronic microbial infections or autoimmune disorders, developing in extranodal sites that normally lack lymphoid tissue.3–5 Gastric MALT lymphoma is the most extensively studied among the various subtypes, primarily linked to chronic Helicobacter pylori gastritis.6 In contrast, salivary gland MALT lymphoma is less common and often associated with chronic inflammation and lymphoid hyperplasia due to autoimmune conditions like Sjogren syndrome (SS) or hepatitis C virus infection.1,7–9 Despite their shared classification, extra-gastric forms, particularly those involving the salivary glands, remain poorly characterized, especially concerning optimal therapeutic approaches.10–12 Histologically, salivary gland MALT lymphomas are marked by slow progression and localized growth, yet their management is complicated by anatomical intricacies, potential functional deficits, and a paucity of high-quality evidence on treatment efficacy.

    Given the indolent nature of MALT lymphoma, immediate intervention is not always necessary, and a consensus on the optimal treatment modality remains elusive. For stage I–II extranodal MALT lymphoma, the National Comprehensive Cancer Network (NCCN) guidelines propose involved site radiation therapy (ISRT), surgery, or rituximab as potential treatment options.13 Active surveillance (watch-and-wait) is a viable strategy for asymptomatic patients.2,14 However, while local surgery or radiotherapy is recommended for primary sites such as the lung, breast, thyroid, and colon/small bowel, specific guidelines for salivary gland MALT lymphoma are lacking.13 Early-stage (I–II) MALT lymphoma is generally considered curable, with treatment strategies focusing on localized interventions to balance oncological control with functional and cosmetic preservation. Nonetheless, significant controversy persists regarding the most effective approach.15 This study aimed to systematically evaluate survival outcomes associated with initial treatment strategies, including surgery alone, radiotherapy alone, combined treatment, chemotherapy alone, or observation in early-stage salivary gland MALT lymphoma. By addressing these knowledge gaps, the findings could refine personalized treatment algorithms, reduce unnecessary therapies, and enhance patient care for this understudied lymphoma subtype.

    Patients and Materials

    Patients

    This study investigated the incidence, initial treatment patterns, and survival outcomes of patients diagnosed with salivary gland MALT lymphoma between 2000 and 2021 using the Surveillance, Epidemiology, and End Results (SEER) database.16 The SEER database, a comprehensive cancer registry in the United States, was utilized to identify cases of MALT lymphoma (International Classification of Diseases for Oncology [ICD-O-3] code 9699/3). Inclusion criteria comprised: 1) a diagnosis of stage I–II salivary gland MALT lymphoma based on the Ann Arbor staging system; 2) availability of data on initial treatment modalities, including surgery, radiotherapy, chemotherapy, or observation (no recorded treatment). Exclusion criteria included patients with unknown staging, secondary primary malignancies, or unspecified radiotherapeutic methods. The study was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University (approval number XMFHIIT-2025SL156), and informed consent was waived due to the retrospective nature of the study.

    Variables

    The analysis incorporated the following variables: age, gender, race/ethnicity, Ann Arbor stage, tumor location, presence of B symptoms, and initial treatment modalities (surgery alone, radiotherapy alone, surgery combined with radiotherapy, chemotherapy alone, and observation). Survival outcomes were assessed using cancer-specific survival (CSS) and overall survival (OS). CSS was defined as the time from MALT lymphoma diagnosis to death attributable to lymphoma, while OS was measured from diagnosis to death from any cause.

    Statistical Analysis

    Baseline patient characteristics across treatment groups were compared using the Chi-square test or Fisher’s exact test. Survival outcomes were evaluated using the Kaplan-Meier method, with Log rank tests employed to compare survival curves. Multivariate Cox proportional-hazards models were used to identify independent prognostic factors for CSS and OS. Sensitivity analyses were conducted to assess the impact of initial treatment modalities on CSS and OS, stratified by gender, race, age, tumor location, tumor stage, and B symptoms. All statistical analyses were performed using the IBM SPSS version (SPSS Inc., Chicago, IL, USA), with a significance threshold of P < 0.05.

    Results

    Patient Characteristics

    A total of 892 patients met the inclusion criteria (Figure 1), with a median age at diagnosis of 59 years. The baseline characteristics of the patients are summarized in Table 1. The majority were female (n=651, 73.0%), Non-Hispanic White (n=528, 59.2%), and had stage I disease (n=649, 72.8%). Tumor location was known for 859 patients, with 740 (86.1%) located in the parotid gland, 116 (13.5%) in the submandibular gland, and 3 (0.3%) in the sublingual gland. Among 432 patients with recorded B symptoms, 31 (7.2%) presented with B symptoms.

    Table 1 Baseline Characteristics of the Study Cohort

    Figure 1 Flowchart of patient selection.

    Treatment Patterns

    Of the patients, 237 (26.6%) underwent surgery alone (included 44 patients receipt of chemotherapy), 202 (22.6%) received radiotherapy alone (included 20 patients receipt of chemotherapy), 170 (19.1%) underwent surgery combined with radiotherapy (included 14 patients receipt of chemotherapy), 53 (5.9%) received chemotherapy alone, and 230 (25.8%) had no recorded treatment information (observation). Patients aged >65 years were more likely to undergo surgery alone, chemotherapy alone, or observation, and less likely to receive surgery combined with radiotherapy or chemotherapy alone (P<0.001). Patients with tumors in the submandibular gland were more likely to receive radiotherapy alone, chemotherapy alone, or observation, while those with tumors in the parotid gland were more likely to undergo surgery or surgery combined with radiotherapy (P<0.001). Additionally, patients with stage II disease were more likely to receive chemotherapy or observation (P<0.001) (Table 1). In earlier years of diagnosis, surgery or surgery combined with radiotherapy was the predominant treatment, while in recent years, the proportion of patients undergoing observation has significantly increased (P=0.004) (Figure 2).

    Figure 2 The percentage of the receipt of initial treatment strategies over the years.

    Survival Analysis

    The median follow-up time for all patients was 92 months (range, 0–262 months). During this period, 209 patients died, including 47 deaths attributed to lymphoma-related causes. The 8-year cancer-specific survival (CSS) and overall survival (OS) rates were 95.6% and 81.8%, respectively. The treatment modality did not significantly affect CSS or OS. The 8-year CSS rates for patients undergoing surgery alone, radiotherapy alone, surgery combined with radiotherapy, chemotherapy alone, and observation were 96.1%, 94.9%, 97.0%, 92.1%, and 95.5%, respectively (P=0.827) (Figure 3A). The 8-year OS rates for these groups were 79.7%, 84.5%, 86.3%, 77.7%, and 79.5%, respectively (P=0.132) (Figure 3B).

    Figure 3 The effect of initial treatment strategies on cancer-specific survival (A) and overall survival (B).

    Prognostic Analysis

    Multivariate analysis was performed to identify independent prognostic factors for CSS and OS (Table 2). Age was identified as an independent prognostic factor for CSS, with patients aged 50–64 years having significantly better CSS than those aged >65 years (hazard ratio [HR] 0.366, 95% confidence interval [CI] 0.190–0.704, P=0.003) (Figure 4A). However, initial treatment modality, gender, race/ethnicity, tumor location, and tumor stage did not significantly affect CSS. For OS, multivariate analysis indicated that gender and age were independent prognostic factors. Female patients had significantly better OS than male patients (HR 0.723, 95% CI 0.531–0.984, P=0.039). Additionally, patients aged 50–64 years (HR 0.018, 95% CI 0.006–0.048, P<0.001) and those aged <50 years (HR 0.221, 95% CI 0.159–0.311, P<0.001) had significantly better OS than patients aged >65 years (Figure 4B).

    Table 2 Multivariate Cox Proportional-Hazards Analysis of Prognostic Factors for Cancer-Specific Survival and Overall Survival

    Figure 4 The effect of age on cancer-specific survival (A) and overall survival (B).

    Sensitivity Analysis

    Sensitivity analysis was conducted to evaluate the impact of different initial treatment modalities on CSS and OS. The results showed that, regardless of gender, race, age, tumor location, tumor stage, or B symptoms, initial treatment modality did not significantly affect CSS or OS (Tables 3 and 4).

    Table 3 Sensitivity Analysis to Evaluate the Impact of Different Initial Treatment Modalities on Cancer-Specific Survival According to Different Patient Characteristics

    Table 4 Sensitivity Analysis to Evaluate the Impact of Different Initial Treatment Modalities on Overall Survival According to Different Patient Characteristics

    Discussion

    This study offers a detailed evaluation of the influence of various treatment modalities on survival outcomes in 892 patients with stage I–II salivary gland MALT lymphoma, representing one of the largest cohorts to address regional treatment variations. Our findings demonstrate an exceptionally favorable prognosis in this patient subset, with no statistically significant differences in survival outcomes observed across initial treatment strategies.

    Salivary glands are the most commonly affected extra-gastric site for MALT lymphoma, accounting for approximately 10% of cases.17,18 While lymphomas constitute only 5–10% of all salivary gland tumors,9,19 MALT lymphoma is the predominant subtype, representing 50–77.5% of salivary gland lymphomas.12,20 Similar to MALT lymphoma in other sites,21–23 salivary gland MALT lymphoma is characterized by a high OS rate. A previous study reported a median OS of 18.3 years and a progression-free survival (PFS) of 9.3 years following initial treatment.24 In our cohort, with a median follow-up of 92 months, the 8-year CSS and OS rates were 95.6% and 81.8%, respectively. Notably, B symptoms were present in only 7.2% of patients with documented symptoms, consistent with findings from a study of primary SS-associated lymphoma, where 76.0% of cases were MALT lymphomas and only 3.2% exhibited B symptoms.25 These results underscore the indolent nature and favorable prognosis of salivary gland MALT lymphoma. The indolent progression pattern of this lymphoma subtype implies that immediate aggressive treatment may not always be necessary. This slow-growing characteristic is crucial in understanding why active surveillance is a viable strategy for a significant proportion of patients. As time passed, we observed an increasing proportion of cases under observation, which might be due to the recognition of this indolent behavior.

    The female predominance (73.0%) observed in our cohort aligns with prior studies, likely reflecting the higher incidence of SS and hepatitis C virus infection among women, both of which are risk factors for MALT lymphoma.18,26 For instance, non-Hodgkin lymphomas develop in 5–10% of primary SS patients, with 70% of these being MALT lymphomas, predominantly affecting the parotid glands.10,12,27 Although the SEER database does not capture autoimmune disease status, previous systematic reviews and multicenter studies have reported that 69.5–75% of salivary gland MALT lymphoma patients are female, with 41–80.2% having concurrent autoimmune disorders, most commonly SS.12,24 This gender disparity may be attributed to the higher prevalence of SS in women and the established association between SS and salivary gland MALT lymphoma. Further research is needed to elucidate the underlying mechanisms driving this gender imbalance.

    In our study, 131 patients (14.7%) received chemotherapy. Among them, the percentages of patients who received chemotherapy in the groups of surgery alone, radiotherapy alone, and surgery combined with radiotherapy were 18.6%, 9.9%, and 8.2%, respectively. However, several studies have indicated that the rate of patients initially treated with systemic therapy ranges from 25.8% to 37%.24,28 The relatively low chemotherapy acceptance rate in this study may be associated with the disease stages of patients, as all the patients included in our study were in stages I–II. In a study by Zhang et al, for 105 patients with head and neck MALT lymphoma (53 cases occurred in the parotid gland), the rate of patients in stages I–II receiving chemotherapy and/or rituximab was lower than that of patients in stages III–IV (21.9% vs 59.4%).29 Additionally, the SEER database does not record the status of patients receiving rituximab, which may also lead to an underestimation of systemic therapy.

    The indolent nature of salivary gland MALT lymphoma has led to a lack of consensus on optimal treatment strategies. For stage I–II extranodal MALT lymphoma, the NCCN guidelines suggest ISRT, surgery, rituximab, or active surveillance as viable options.13 However, specific recommendations for salivary gland MALT lymphoma remain undefined. In our study, 45.7% of patients underwent surgery with or without radiotherapy, 22.6% received radiotherapy alone, 5.9% were treated with chemotherapy alone, and 25.8% were managed with observation. A prior systematic review of 374 parotid gland MALT lymphoma cases reported treatment distributions of 13.3% surgery alone, 42.7% chemotherapy alone, 18.7% radiotherapy alone, 8.0% combined chemotherapy and radiotherapy, and 17.3% watchful waiting.12 Similarly, a multicenter international cohort of 248 patients found that 57% received surgery, radiotherapy, or both, 37% underwent systemic therapy, and 6% were observed.24 These variations highlight the absence of a standardized treatment approach. Interestingly, our study noted a significant increase in the proportion of patients managed with observation in recent years (P=0.004), reflecting a potential shift toward more conservative strategies. This trend may be driven by the indolent nature of the disease, concerns about overtreatment, and a growing emphasis on preserving quality of life. Advances in diagnostic accuracy and surveillance protocols may also contribute to increased clinician confidence in deferring immediate intervention. However, the long-term implications of this approach, particularly regarding disease progression and survival outcomes, warrant further investigation.

    Our investigation reveals that the absence of significant disparities in CSS and OS across various treatment modalities (surgery alone, radiotherapy alone, surgery combined with radiotherapy, chemotherapy alone, and observation), implies that the initial treatment choice may not be a pivotal factor in determining survival outcomes for stage I–II salivary gland MALT lymphoma. This observation aligns with the indolent nature of MALT lymphoma, characterized by slow disease progression, where survival is predominantly influenced by patient-specific factors such as age and gender rather than the treatment modality employed. Another reason might be that the early-stage nature of this disease in our study plays a role. In early-stage salivary gland MALT lymphoma, the tumor may be more localized and less invasive, and thus different treatment modalities may have similar effectiveness in achieving oncological control. The uniformly high survival rates across all groups (8-year CSS: 92.1%-97.0%; 8-year OS: 77.7–86.3%) further underscore the generally favorable prognosis of early-stage disease, irrespective of the therapeutic approach. Consistent with our findings, Jackson et al reported a median OS of 18.3 years and a median progression-free survival (PFS) of 9.3 years following primary therapy, with no significant differences in outcomes between patients receiving local (surgery, surgery plus radiotherapy, or radiotherapy alone) or systemic therapy in first-line management of stage I–II disease.24 Similarly, Wen et al included 84 patients with salivary gland MALT lymphoma and found no significant difference in PFS between surgical and conservative treatment groups.30 Parallel outcomes have been documented in MALT lymphomas affecting other anatomical sites. For instance, studies on colon MALT lymphoma also indicate no substantial survival differences among patients treated with local therapy, chemotherapy, or observation.21 Nonetheless, close follow-up is essential, as approximately 31% of patients may experience disease progression post-treatment, including recurrence in the ipsilateral salivary gland or neck (29.4%), contralateral salivary gland (31.4%), and distant sites (39.2%).24 Another study indicated that in MALT patients with primary SS, the 5-year and 10-year event-free survival rates were 63.6% and 45.5%, respectively.25 Moreover, antibiotic therapy emerges as a viable treatment option. In a study of 28 patients with extranodal MALT lymphoma treated with antibiotics as first-line therapy, including four with parotid gland MALT lymphoma, only one patient experienced disease progression after five years, while the remaining three remained disease-free during a follow-up period of 5.0–7.7 years.31 These findings collectively highlight a universal survival advantage for localized salivary gland MALT lymphoma, regardless of the initial management strategy.

    Given the excellent outcomes across all treatment strategies, it is imperative to consider the side-effect profile and potential long-term complications when tailoring treatment to individual patients. MALT lymphomas originating from the orbit and ocular adnexa may adversely affect the cosmetic outcomes of the ocular and surrounding tissues with local surgical treatment. In contrast, radiotherapy may offer advantages in preserving the organs and mitigating potential cosmetic adverse effects, while also demonstrating excellent local control rates (5-year local control rate of 98%).32 Nonetheless, in cases of intestinal MALT, surgical procedures continue to be crucial for acquiring biopsy samples and enabling accurate pathological assessment.33 Parotidectomy, often performed for diagnostic purposes, was considered curative in about one-fifth of surgical cases, with no further treatment required. For localized MALT lymphomas, unimodal treatment is often deemed sufficient.34,35 Both surgery and radiotherapy are equally effective in our study and previous research.34,35 However, it is crucial to recognize that a significant proportion of patients with salivary gland MALT lymphomas also suffer from SS. For non-gastric MALT lymphomas, ISRT at doses of 20–24 Gy is recommended.14,36 Regarding the functional impairments of different treatment modalities, irradiation of the salivary gland may exacerbate gland dysfunction, leading to xerostomia and associated complications such as altered appetite, impaired swallowing, increased dental caries, and permanent dietary modifications.37,38 In our study, a substantial number of patients received radiotherapy either alone or in combination with surgery. Therefore, the potential long-term local toxicities must be carefully weighed against the side effects of cytotoxic therapy, especially given the prolonged survival expected in most patients. Future research should quantify the incidence and severity of xerostomia and other functional impairments associated with radiotherapy and other treatment methods. This information can help in making more informed treatment decisions, especially when balancing the potential benefits of treatment against its side effects.

    Multivariate analysis in our study identified age and gender as independent prognostic factors for survival outcomes, with younger patients and females demonstrating superior survival rates. The protective effect of younger age may be attributed to better overall health and treatment tolerance, while the superior OS in females could be linked to hormonal or immunological factors. These findings underscore the necessity for personalized treatment strategies informed by tumor biology and patient-specific risks. Jackson et al found that age <60 years and a low to intermediate international prognostic index were associated with improved OS and PFS, and the presence of SS was linked to better OS.24 Conversely, Zhang et al reported that patients without SS had prolonged recurrence-free survival compared to those with SS.28 Additionally, several studies have implicated Trisomy 18 in predicting tumor relapse.28,39 Interestingly, tumor stage did not significantly impact CSS or OS, further emphasizing the importance of patient-specific factors in determining outcomes.

    Several limitations of this study should be acknowledged. First, its retrospective nature introduces potential biases, including selection bias and unmeasured confounding factors. Second, the lack of detailed data on Sjögren’s syndrome status, treatment regimens, dosages, and compliance limits the ability to assess the impact of specific therapeutic approaches. Third, the long follow-up period (median 92 months) may have introduced variability in treatment practices over time, particularly with the increasing use of observation. Future prospective studies are needed to validate the long-term safety of observation strategies in this patient subset. Additionally, the relatively small number of patients in certain subgroups (eg, chemotherapy alone, n=53) may have limited the statistical power to detect differences in survival outcomes. Finally, the absence of data on recurrence rates, long-term toxicity, or quality-of-life metrics may still influence treatment decisions.

    Conclusions

    In conclusion, this study highlights that stage I–II salivary gland MALT lymphoma is characterized by a female predominance and an increasing trend toward observation as a management strategy. The lack of significant survival differences across treatment modalities suggests that the choice of initial treatment may be less critical than patient-specific factors such as age and gender. However, further clarification is required regarding the selection criteria for the observation group, particularly whether these patients were primarily low-risk cases, as this could significantly influence the interpretation of the findings. Additionally, the potential impact of treatment selection bias, evidenced by the notably lower utilization of chemotherapy in our cohort compared to other studies, necessitates further investigation to ensure the generalizability and robustness of our results. Furthermore, the growing adoption of the observation strategy highlighted in this study should be substantiated with functional outcome data, such as quality of life assessments, to provide a more comprehensive evaluation of its clinical benefits and potential limitations. These findings advocate for personalized treatment approaches and underscore the importance of further research to better understand the underlying mechanisms driving gender disparities and the long-term outcomes of conservative management strategies. Future prospective studies with standardized treatment protocols and detailed patient data are warranted to refine treatment guidelines, prioritizing both efficacy and the minimization of treatment-related harms for this rare malignancy.

    Data Sharing Statement

    The datasets used and/or analyzed during the current study are available from the corresponding author Dr. San-Gang Wu upon reasonable request.

    Ethics Approval and Consent to Participate

    The study was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University (approval number XMFHIIT-2025SL156), and informed consent was waived due to the retrospective nature of the study.

    Acknowledgments

    The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in creating the SEER database.

    Author Contributions

    All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

    Funding

    There is no funding to report.

    Disclosure

    The authors declare that they have no competing interests in this work.

    References

    1. Travaglino A, Giordano C, Pace M, et al. Sjögren syndrome in primary salivary gland lymphoma. Am J Clin Pathol. 2020;153(6):719–724. doi:10.1093/ajcp/aqaa005

    2. Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17–29. doi:10.1016/j.annonc.2019.10.010

    3. Zhang Q, Yan W, Li H, et al. Advances in the pathogenesis, diagnosis, treatment, and prognosis of marginal zone lymphoma. Curr Treat Options Oncol. 2025;26(2):142–155. doi:10.1007/s11864-025-01293-w

    4. Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66(2):153–171. doi:10.3322/caac.21330

    5. Segura-Rivera R, Pina-Oviedo S. Marginal zone lymphoma of extranodal sites: a review with an emphasis on diagnostic pitfalls and differential diagnosis with reactive conditions. Hum Pathol. 2025;156:105683. doi:10.1016/j.humpath.2024.105683

    6. Hu Q, Zhang Y, Zhang X, et al. Gastric mucosa-associated lymphoid tissue lymphoma and helicobacter pylori infection: a review of current diagnosis and management. Biomark Res. 2016;4(1):15. doi:10.1186/s40364-016-0068-1

    7. Aydın S, Demir MG, Barışık NÖ. Extranodal marginal zone lymphoma of the parotid gland. J Maxillofac Oral Surg. 2016;15(Suppl 2):346–350. doi:10.1007/s12663-016-0882-x

    8. Mezei T, Mocan S, Ormenisan A, et al. The value of fine needle aspiration cytology in the clinical management of rare salivary gland tumors. J Appl Oral Sci. 2018;26:e20170267.

    9. Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18(2):346–350. doi:10.1093/annonc/mdl388

    10. Verstappen GM, Pringle S, Bootsma H, et al. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat Rev Rheumatol. 2021;17(6):333–348. doi:10.1038/s41584-021-00605-2

    11. Quintanilla-Martinez L, Fend F. Turning up the heat on salivary gland MALT lymphoma. Blood. 2022;139(14):2094–2096. doi:10.1182/blood.2021012624

    12. Di Santo D, Bramati C, Festa BM, et al. Current evidence on diagnosis and treatment of parotid gland lymphomas: a systematic review. Eur Arch Otorhinolaryngol. 2023;280(12):5219–5227. doi:10.1007/s00405-023-08206-3

    13. National Comprehensive Cancer Network. (NCCN) clinical practice guidelines in oncology. B-cell lymphomas 2025. Version 2. Version 2: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed March 06, 2025.

    14. Pirosa MC, Stathis A, Rossi D, et al. SOHO state of the art updates and next questions: treatment options for marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2025;25(7):S2152–2650. doi:10.1016/j.clml.2025.02.002

    15. Kaddu-Mulindwa D, Thurner L, Christofyllakis K, et al. Management of extranodal marginal zone lymphoma: present and upcoming perspectives. Cancers. 2022;14(12):3019. doi:10.3390/cancers14123019

    16. Surveillance, Epidemiology, and End Results Program Surveillance, epidemiology, and end results (SEER) program (www.Seer.cancer.gov) SEER*Stat database: incidence – SEER research Data, 17 registries, Nov 2022 sub (2000-2020) – linked to county attributes – time dependent (1990-2021 Surveillance, epidemiology, and end results (SEER) program (www.Seer.cancer.gov) SEER*Stat database: incidence – SEER research Data, 17 registries, Nov 2022 sub (2000-2020) – linked to county attributes – time dependent (1990-2021. Surveillance, epidemiology, and end results (SEER) program (www.Seer.cancer.gov) SEER*Stat database: incidence – SEER research Data, 17 registries, Nov 2022 sub (2000-2020) – linked to county attributes – time dependent (1990-2021. Income/Rurality, 1969-2021 Cties, Natl Cancer Inst, DCCPS. Surveillance Research Program, released, based on the submission. Accessed March 6, 2025.

    17. Wu Y, Liu X, Imber BS, et al. Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: a SEER database analysis (2000-2015). Radiother Oncol. 2022;173:179–187. doi:10.1016/j.radonc.2022.05.034

    18. Matutes E, Montalban C. Clinical features and management of non-gastrointestinal non-ocular extranodal mucosa associated lymphoid tissue (ENMALT) marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30(1–2):99–108. doi:10.1016/j.beha.2016.07.005

    19. Zhu L, Wang P, Yang J, et al. Non-Hodgkin lymphoma involving the parotid gland: CT and MR imaging findings. Dentomaxillofac Radiol. 2013;42(9):20130046. doi:10.1259/dmfr.20130046

    20. Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin’s lymphomas. part 2: head and neck, central nervous system and other less common sites. Ann Oncol. 1999;10(9):1023–1033. doi:10.1023/A:1008313229892

    21. Trabolsi A, Alderuccio JP, Florindez J, et al. Marginal zone lymphoma of the colon: case series from a single center and SEER data review. Leuk Lymphoma. 2022;63(5):1160–1166. doi:10.1080/10428194.2021.2015766

    22. Khalil MO, Morton LM, Devesa SS, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol. 2014;165(1):67–77. doi:10.1111/bjh.12730

    23. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016;127(17):2082–2092. doi:10.1182/blood-2015-12-624304

    24. Jackson AE, Mian M, Kalpadakis C, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41). Oncologist. 2015;20(10):1149–1153. doi:10.1634/theoncologist.2015-0180

    25. Chatzis LG, Stergiou IE, Goules AV, et al. Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: results from a harmonized dataset (1981-2021). Rheumatology. 2022;61(9):3576–3585. doi:10.1093/rheumatology/keab939

    26. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126(1):43–49. doi:10.1111/j.1365-2141.2004.04993.x

    27. Nocturne G. Actualités dans le syndrome de Sjögren primitif: aspects cliniques et thérapeutiques [Sjögren’s syndrome update: clinical and therapeutic aspects]. Rev Med Interne. 201940(7):433–439.

    28. Zhang C, Xia R, Gu T, et al. Clinicopathological aspects of primary mucosa-associated lymphoid tissue lymphoma of the salivary gland: a retrospective single-center analysis of 72 cases. J Oral Pathol Med. 2021;50(7):723–730. doi:10.1111/jop.13168

    29. Zhang T, Wu Y, Ju H, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: a retrospective analysis of 105 patients. Cancer Med. 2020;9(1):194–203. doi:10.1002/cam4.2681

    30. Wen X, Hu Y, Liu Y, et al. Conservative treatment of head and neck lymphoma is not the only effective treatment: a retrospective analysis of 301 cases. Oral Oncol. 2022;128:105828. doi:10.1016/j.oraloncology.2022.105828

    31. Yao M, Liao SL, Lin CW, et al. First-line antibiotic treatment in patients with localized extragastric mucosa-associated lymphoid tissue lymphoma. EJHaem. 2022;4(1):55–66. doi:10.1002/jha2.608

    32. La Rocca M, Leonardi BF, Lo Greco MC, et al. Radiotherapy of orbital and ocular adnexa lymphoma: literature review and university of catania experience. Cancers. 2023;15(24):5782. doi:10.3390/cancers15245782

    33. Pham MD, Nguyen MT, Pham NTT. Ileal mucosa-associated lymphoid tissue lymphoma diagnosed after emergency surgery: a case report and literature review. Annals Med Surg. 2021;71:102973. doi:10.1016/j.amsu.2021.102973

    34. Vazquez A, Khan MN, Sanghvi S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009. Head Neck. 2015;37(1):18–22. doi:10.1002/hed.23543

    35. Malek SN, Hatfield AJ, Flinn IW. MALT Lymphomas. Curr Treat Options Oncol. 2003;4(4):269–279. doi:10.1007/s11864-003-0002-2

    36. Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, Phase 3, non-inferiority trial. Lancet Oncol. 2021;22(3):332–340. doi:10.1016/S1470-2045(20)30686-0

    37. Gunther JR, Park C, Dabaja BS, et al. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020;61(1):171–175. doi:10.1080/10428194.2019.1644333

    38. Moroney LB, Helios J, Ward EC, et al. Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. Support Care Cancer. 2019;27(2):573–581. doi:10.1007/s00520-018-4352-5

    39. Streubel B, Simonitsch-Klupp I, Müllauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18(10):1722–1726. doi:10.1038/sj.leu.2403501

    Continue Reading

  • 5 takeaways from Taylor Swift’s unprecedented podcast interview – The Washington Post

    1. 5 takeaways from Taylor Swift’s unprecedented podcast interview  The Washington Post
    2. Taylor Swift Says She Collapsed Into Travis Kelce’s Arms When She Learned She Got Her Masters Back, ‘Bawling My Eyes Out’  yahoo.com
    3. ‘I got my music back!’ Teary-eyed Taylor reveals how her mother cracked $360 mn Shamrock deal  financialexpress.com
    4. Taylor Swift breaks down in tears detailing how she got her masters back after Scooter Braun battle  Entertainment Weekly
    5. 7 takeaways from Taylor Swift’s appearance on the ‘New Heights’ podcast  Business Insider

    Continue Reading

  • New Sonderwunsch project: Porsche’s first Transfăgărășan tribute hits the road

    New Sonderwunsch project: Porsche’s first Transfăgărășan tribute hits the road




    The first example of a special-edition 911 Carrera 4 GTS that celebrates 50 years of one of the world’s most beautiful roads has been delivered to its Romanian owner.


    Passing over the Făgăraş mountains and linking the Romanian regions of Muntenia and Transylvania by way of 90 sweeping kilometres of ribbon-like asphalt, the Transfăgărășan is widely acknowledged as one of the world’s greatest highways. 

    When the ‘road that touches the clouds’ turned 50 years old in 2024, so too did the 911 Turbo, leading to the Porsche clubs of Romania and Moldova organising a driving event on the route that featured some 110 cars and 200 guests.

    Around the same time, inspired by half a century of the legendary route, the Porsche Sonderwunsch team in Zuffenhausen began work on a very special celebratory model: the 911 Carrera 4 GTS ‘Tribute to Transfăgărășan’. Just 10 of these cars would be built, each customised down to the smallest details by their future owner together with the Sonderwunsch and Style Porsche experts. Now, a year on, the first of the cars has been delivered to its new home in Romania, starting with a drive on the Transfăgărășan itself.

    “When we experienced the Transfăgărășan during the 911 Turbo’s 50th anniversary last year, we found a lot of inspiration for this individualisation package,” explains Alexander Fabig, Vice President Individualisation & Classic at Porsche. “Therefore, we decided to not only create one but 10 individualised cars that pay tribute to one of the most legendary and inspiring parts of Romania.”   

    The ‘hero car’ in detail

    Finished in the Paint to Sample colour Graphite Grey, the first of the 10 cars sits on wheels with contrasting spokes painted in Guards Red while the same shade rings the headlights, adding a striking visual accent to the vehicle’s front end. On the doors, a subtle ‘Tribute to Transfăgărășan’ decal is displayed, while the B-pillars feature a badge that marks the vehicle out as one of the 10 special editions. At the rear, the engine grille slats are discreetly painted blue, yellow and red – the colours of the Romanian flag.

    Inside the car, the personal touches continue, with ‘Tribute to Transfăgărășan’ featuring on the illuminated door sill guards, embroidered into the headrests and embossed on the centre armrest. The passenger-side dashboard also features the logo and lettering.

    Individualisation via the Sonderwunsch programme

    While all 10 vehicles feature the commemorative exterior badging, Romanian flag accents and bespoke interior elements, each was also individually configured by its future owner through the Porsche Sonderwunsch programme, with some choosing custom paint finishes, different interior materials, and picking from a selection of accessories. The result is that each car is one of a kind, united by the common tribute that the series pays to one of the world’s most iconic driving roads.

    911 Carrera 4 GTS “Tribute to Transfăgărășan“, Sonderwunsch, Romania, 2025, Porsche AG





    The customers were given a sneak preview earlier this year, when they visited the Sonderwunsch Manufaktur in Zuffenhausen, and discussed the final details of their cars with the Sonderwunsch specialists there. The nine who have yet to receive their four-wheeled tributes will do so at an event at the end of August.

    Adrian Pascu from Porsche Inter Auto Romania said: “The Transfăgărășan’ is well-known by car enthusiasts all over the world for its magnificent landscapes and its hairpin turns and I look forward to seeing these exceptional cars being driven on the very road they are honouring.”

    Super-lightweight performance hybrid

    As is often the case with Porsche sports cars, the new 911 Carrera GTS models benefit from the knowledge gained by Porsche engineers from the world of motor racing. In this case, it particularly influenced the design of the T-Hybrid drive, at the heart of which is a newly developed 3.6-litre boxer engine (911 Carrera GTS: Fuel consumption* combined (WLTP) 11.0 – 10.4 l/100 km, CO₂ emissions* combined (WLTP) 248 – 236 g/km, CO₂ class G , CO₂ class weighted combined G ).

    911 Carrera 4 GTS “Tribute to Transfăgărășan“, Sonderwunsch, Romania, 2025, Porsche AG




    911 Carrera 4 GTS: Fuel consumption* combined (WLTP) 11.0 – 10.4 l/100 km, CO₂ emissions* combined (WLTP) 249 – 236 g/km, CO₂ class G , CO₂ class weighted combined G

    Its impressive performance enables the 911 Carrera 4 GTS Coupé to complete the 0-100 km/h sprint in 3.0 seconds, while it has a top speed of 312 km/h. In total, the system output is 398 kW (541 PS) and 610 Nm. The power increase over the predecessor model is 45 kW (61 PS). The new 911 Carrera 4 GTS offers highly dynamic driving characteristics while reducing CO₂ emissions and weighing significantly less compared to plug-in hybrid vehicles. The weight increase over its predecessor is just 50 kilograms.

    About Porsche Sonderwunsch

    Porsche has reinterpreted the legendary Sonderwunsch (special request) programme of the late 1970s, to take personalisation to the highest level. It enables personalised one-off cars that are created in partnership with the customer and realised by Porsche’s experts.

    Customers can choose to have their car built with individual options fitted directly at the factory, before delivery takes place. One of the highlights of the programme is Paint to Sample Plus, which opens up a new world of individual exterior colour options. Factory Re-Commissioning of vehicles is also possible. Customers can completely redesign the interior and exterior of their car or create highly individualised one-offs with the support of Porsche’s own development and design teams. For older cars, this offering includes restoration, which can also be commissioned separately.

    Continue Reading

  • Porsche Golf Circle celebrates festival on Sylt – with surprise guest

    Porsche Golf Circle celebrates festival on Sylt – with surprise guest




    Unique setting, high‑class sport and the special spirit of the community: The Porsche Golf Circle Festival Sylt delivered a day filled with competition, festival vibes, longtime friends and new connections – framed by dunes and the ocean breeze on the links course at Golfclub Budersand. One highlight was a special surprise guest Paul Casey.


    The second Porsche Golf Circle Festival of the year unfolded at the stunning Golfclub Budersand in Hörnum. After several successful festivals of the community in Mallorca in recent years, Sylt now delighted members from all over Germany and Sweden as a spectacular venue for a second festival in one summer – and the next chapter in the festival series. “It’s great that the Porsche Golf Circle Festival is now also taking place in Germany,” said one participant.

    As the first light of day stretched over the North Sea, new faces were welcomed and old friendships were rekindled over fresh coffee, cool refreshments, and a light morning snack. Two optional wake‑up yoga sessions helped warm up both muscles and minds, building balance, focus, and fresh energy for the day ahead – perfect preparation for the unique links course challenge that awaited.

    Porsche Golf Circle, Sylt, Germany, 2025, Porsche AG




    Golfclub Budersand

    Tricky tasks on one of the outstanding links courses

    From the shotgun start to the final putt, the course of the Budersand Golf Club – one of Germany’s top golf destinations – demanded skill and rewarded courage. The wind provided tricky tasks, but the camaraderie kept spirits high. Laughter, encouragement, and shared moments filled the fairways, with refreshing drinks and tasty bites along the way.

    The competitive edge was still sharp, with net and gross categories plus Longest Drive and Nearest to the Pin contests adding extra excitement. A standout performance came from Carlos Delfs, whose shot in the Nearest to the Pin competition stopped just seven centimetres from the hole. In the end, the German Circle member played a very strong round of 71 (-1) on the challenging course.

    Porsche Golf Circle, Sylt, Germany, 2025, Porsche AG





    A surprise guest on the 4th

    Just before tee‑off, a sharp‑eyed participant had spotted someone in the car park who looked a lot like world‑class golfer Paul Casey. “Are you the real Paul Casey?” the member asked. He was – and he wasn’t just there to watch. The Porsche Brand Ambassador, and fellow Porsche Golf Circle member, was waiting on the 4th hole for a Beat the Pro challenge. And yes – one member actually did beat the pro. England’s three-time Ryder Cup champion also took the time to walk the course with the players, offering insights and sharing a few expert tips along the way.

    Paul Casey (r), Porsche Golf Circle, Sylt, Germany, 2025, Porsche AG




    Beat the Pro with Paul Casey

    “It was great to be back with the Porsche Golf Circle family – wonderful conversations, familiar faces, new connections, and some impressive golf shots by the members. The challenge was, as always, a lot of fun!” said Paul Casey, who climbed to third place in the world rankings during his career.

    While golfers battled the course, non‑golfing companions enjoyed a slower pace – with a yoga session nestled in the heart of the Hörnum dunes. Flowing movements, mindful breathing, and North Sea tranquility made for a calming reset in nature.

    Porsche Golf Circle, Sylt, Germany, 2025, Porsche AG




    Yoga session near the North Sea

    From competition to celebration

    By late afternoon, the action shifted from the fairways to the terrace of the Golfclub Budersand with lounge beats, food and drinks. The atmosphere was equal parts relaxed and celebratory. Guests also enjoyed an exclusive preview of the new Porsche Golf Collection by Porsche Lifestyle, offering a first look at premium apparel and accessories designed for performance and style on and off the course. The award ceremony recognised the day’s best performances, but the real prize was the familiar spirit of the Porsche Golf Circle with laughter, connections and a lot of talking points.

    As night fell, the atmosphere reached its peak – with a DJ and live singer keeping the dance floor full until the very end. The evening then closed with one final highlight: a spectacular fireworks display over Hörnum, staged as part of the Hörnum Harbor Festival and enjoyed from the best seats. A dazzling finale to an unforgettable day.

    Porsche Golf Circle, Sylt, Germany, 2025, Porsche AG




    All winners of the Porsche Golf Circle Festival Sylt

    “Following the success of the events in Mallorca, bringing this unique format to our customers in Germany felt like a natural next step. Experiencing the Porsche Golf Circle spirit together on the island of Sylt – surrounded by individuals who share the same passion for Porsche and Golf – was truly extraordinary and a powerful reflection of our global Porsche community,” said Maximilian Ramisch, Manager Brand Strategy and Partnerships at Porsche Germany.

    Test drives with Macan and Taycan

    The following morning, the festival offered a bonus experience – the Farewell & Drive. Members took the wheel of the latest all-electric Porsche Taycan and Macan models, cruising Sylt’s scenic coastal roads before raising a final toast at the famous beachfront restaurant Sansibar, cooperation partner of Porsche Deutschland. The perfect ending to a weekend of sport, friendship, and unforgettable moments. “You could tell how much heart and soul and passion went into every detail,” enthused one member. And another added: “Another great event!”

    Taycan Turbo Cross Turismo, Porsche Golf Circle, Sylt, Germany, 2025, Porsche AG





    Porsche in Golf

    Porsche has been involved in golf since 1988 through the Porsche Golf Cup. One of the company’s most successful customer events, the tournament series has developed into an international event in which over 16,000 Porsche customers recently took part in 229 worldwide qualifying tournaments. The sports car manufacturer started its involvement in professional golf in Germany in 2015 when becoming the title sponsor of the DP World Tour’s prestigious Porsche European Open. In order to expand its global activities, Porsche has been acting as the title sponsor of the Porsche Singapore Classic in the important Asian market since 2024. Car partnerships at US PGA Tour and DP World Tour tournaments, such as the Omega European Masters in Crans Montana as well as in women’s golf at The Amundi Evian Championship, round off its worldwide commitment in professional golf. Launched in 2017, the Porsche Golf Circle is also highly successful. The international community for keen golf-playing Porsche customers gives members the opportunity to enjoy exclusive golfing experiences at unique locations and at professional tournaments. Paul Casey has been complementing the Porsche family as the first Brand Ambassador from the game of golf since 2020.

    Continue Reading

  • Scientists warn of ‘The Big One’ earthquake predicted to be one of the worst in history

    Experts have issued an urgent warning regarding a supposed upcoming earthquake known as ‘The Big One’.

    Scientists explained that the earthquake could have a magnitude of around 7.7 on the Richter scale and would likely rock the West Coast of the US.

    The news comes just weeks after one of the most powerful earthquakes on record struck the Pacific Ocean, affecting Russia’s Far East and prompting President Trump to issue a warning to those in Hawaii, in particular.

    A new study by Caltech researchers revealed that their analysis of a recent 7.7-magnitude earthquake, which struck Myanmar in March this year, could point towards a harrowing outcome for those near the infamous San Andreas Fault.

    It’s known to be similar to Myanmar’s affected Sagaing fault, and if it’s anything like the natural disaster that hit the region, then Americans could be in trouble.

    An earthquake with a magnitude of 7.7 hit Myanmar in March 2025 (STR/AFP via Getty Images)

    An earthquake with a magnitude of 7.7 hit Myanmar in March 2025 (STR/AFP via Getty Images)

    The earthquake, which hit the Sagaing fault, ended up causing a rupture which ran along a longer section of the fault than expected, causing the deaths of anywhere between 2,000 and 5,500, according to authorities, with thousands more injured.

    Unfortunately, it looks like ‘The Big One’ could be larger than initially predicted as well.

    Both faults are ‘straight strike-slip faults’ which run for hundreds of kilometres, though Jean-Philippe Avouac, the co-author of the study, admitted: “Future earthquakes might not simply repeat past known earthquakes.”

    “Successive ruptures of a given fault, even as simple as the Sagaing or the San Andreas faults, can be very different and can release even more than the deficit of slip since the last event,” he further explained.

    The expert also claimed that historical records are simply ‘far too short’ for any models to present the ‘full range of possible earthquakes’ accurately.

    The natural disaster would cause damage unlike anything we've seen before (Getty Images/ Bob Riha Jr / Contributor)

    The natural disaster would cause damage unlike anything we’ve seen before (Getty Images/ Bob Riha Jr / Contributor)

    When it comes to the Sagaing, the damage caused was down to a territory which ran through the heart of the southeast nation.

    Caltech experts used satellite imagery of the fault’s motion to observe its movement and predict if a similar event could occur in California.

    Solène Antoine, the first author of the study, said that this was an ‘ideal case’ to analyse.

    Previous tremors along the Myanmar fault suggested that if an earthquake were to hit a 186-mile section of the fault, it would be affected, though they were wrong.

    No large earthquakes have occurred here since 1839, but this quake affected an area of over 310 miles, with the section shifting three metres after the incident.

    If ‘The Big One’ were to take place, it’d be nothing we’ve ever seen before at the San Andreas fault, as previous earthquakes had magnitudes of 7.9 in 1857, and 7.9 again in 1906, which ruptured in two directions.

    The San Andreas fault is eerily visible in certain areas (Getty Stock Image)

    The San Andreas fault is eerily visible in certain areas (Getty Stock Image)

    At least 43 large earthquakes have taken place in the Cascadia subduction zone, which runs from Northern California up to northern Vancouver Island, with the last one occurring in January 1700 (via Oregon.gov).

    But for years, experts have claimed that it is building ‘stress’ while remaining locked, and when it does eventually rip, a section of the seafloor will shift forward, causing a tsunami, USGS geophysicist Danny Brothers told NBC News.

    Robert Ezelle, the director of Washington state’s emergency management division, said of a possible earthquake in the region: “It’s going to be the worst natural disaster in our country’s history.”

    Well then, all experts need to do is predict exactly when this will happen.

    Easy enough, right?

    Continue Reading